Outcomes after switching from one bisphosphonate to another in 146 patients at a single university hospital

Outcomes after switching from one anti–t

Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort study

✍ Kimme L. Hyrich; Mark Lunt; Kath D. Watson; Deborah P. M. Symmons; Alan J. Silma 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 1 views

## Abstract ## Objective Patients with rheumatoid arthritis (RA) who experience treatment failure with one anti–tumor necrosis factor (anti‐TNF) agent, due to either inefficacy or toxicity, are frequently switched to a second anti‐TNF agent, although the benefits of switching are unknown. The pres